The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
Abstract
The murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside GD2, activates human complement, is active in antibody-dependent cell-mediated cytotoxicity (ADCC), and can target specifically to human neuroblastoma in patients with metastatic disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with metastatic GD2 positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and 100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused. However, serum antimouse antibody levels did not increase with the amount of 3F8 administered. Toxicities included pain, hypertension, urticaria, and complement depletion. All acute side effects were controllable with symptomatic therapy. No long-term side effects were detected in patients observed for more than 14 months. None of the 17 patients received any antitumor therapy postantibody treatment. Antitumor responses occurred in seven of 17 patients. These ranged from complete clinical remissions to mixed responses. The murine monoclonal antibody (MoAb) 3F8 has clinical utility for the diagnosis and therapy of neuroblastoma and melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Miller, R. A., Maloney, D. G., Warnke, R., & Levy, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198203043060906 · Cited by 985
Houghton, A. N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B., Vadhan, S., Carswell, E., Melamed, M. R., Oettgen, H. F., & Old, L. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.4.1242 · Cited by 566
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
Cheung, N. V., Saarinen, U. M., Neely, J. E., et al. (1985) · PubMed · Cited by 322
Self-citationCheresh, D. A., Pierschbacher, M. D., Herzig, M. A., & Mujoo, K. (1986) · The Journal of cell biology · doi:10.1083/jcb.102.3.688 · Cited by 313
Oldham, R. K., Foon, K. A., Morgan, A. C., Woodhouse, C. S., Schroff, R. W., Abrams, P. G., Fer, M., Schoenberger, C. S., Farrell, M., & Kimball, E. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.11.1235 · Cited by 201
Cheung, N. V., Landmeier, B. J., Neely, J. E., Nelson, A. D., Abramowsky, C. R., Ellery, S., Adams, R. B., & Miraldi, F. D. (1986) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/77.3.739 · Cited by 118
Self-citationEradication of established human melanoma tumors in nude mice by antibody-directed effector cells.
Schulz, G., Staffileno, L. K., Reisfeld, R., & Dennert, G. (1985) · The Journal of Experimental Medicine · doi:10.1084/jem.161.6.1315 · Cited by 66
Cited by
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Self-citationRobust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Auslander, N., Zhang, G., Lee, J. S., Frederick, D. T., Miao, B., Moll, T., Tian, T., Wei, Z., Madan, S., Sullivan, R. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0157-9 · Cited by 738
Metadata
- Authors
- Cheung, N. K., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., & Berger, N. A.
- Venue
- Journal of Clinical Oncology
- Published
- 1987-09
- Volume
- 5
- Issue
- 9
- Pages
- 1430-1440
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1951179504
- Cited by
- 417
- References
- 7
- FWCI
- 18.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. https://app.cochat.ai/papers/10.1200/jco.1987.5.9.1430
- The paper
- Cheung, N. K., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., & Berger, N. A. (1987). Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1987.5.9.1430
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.